Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 101Central Nervous System Neoplasms 37Medulloblastoma 35Brain Neoplasms 33Glioblastoma 20Sarcoma 16Rhabdoid Tumor 14Glioma 13Ependymoma 12Astrocytoma 11Osteosarcoma 10Neuroectodermal Tumors, Primitive 10Recurrence 9Neoplasms 9Lymphoma 9Breast Neoplasms 9Sarcoma, Ewing 8Oligodendroglioma 8Melanoma 8Ganglioneuroblastoma 8Choroid Plexus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Gliosarcoma 7Rhabdomyosarcoma 6Multiple Myeloma 6Wilms Tumor 5

Interventions

Rituximab 2thymoglobulin 1prednylidene 1dexamethasone acetate 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Etoposide 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Carmustine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Opsoclonus-Myoclonus Syndrome × Cyclophosphamide × CNS × Clear all
NCT01868269 2025-02-03

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Institut Curie

Phase 3 Completed
102 enrolled
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡